All In MedTech

Device Trial Radar · NCT07756411

Selective, Micropulse and Pattern Laser Trabeculoplasty in Medically Treated Open-angle Glaucoma.

Subvisible Laser Trabeculoplasty in Medically Treated Open-angle Glaucoma: a Randomized Three-arm Comparison of Selective, Micropulse and Pattern Delivery Protocols.

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Feb 1, 2025

Primary completion

Apr 1, 2026

Study completion May 1, 2026

Sponsor

Lead sponsor
University of UdineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 10, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, single-centre, three-arm trial compared three subvisible laser trabeculoplasty delivery protocols in eyes with open-angle glaucoma already receiving intraocular pressure (IOP)-lowering medication: selective laser trabeculoplasty (SLT, 3-nanosecond pulses), micropulse laser trabeculoplasty (MLT, 577 nm with 15% duty cycle), and pattern laser trabeculoplasty (PLT, 5-ms pattern delivery). Ninety eyes of 90 patients were allocated 1:1:1 to a single 360-degree session and followed for 6 months. The primary outcome was IOP at 6 months, with an equivalence margin of +/-2.0 mmHg prespecified for pairwise comparisons. Secondary outcomes were percentage IOP change, number of IOP-lowering medications, cumulative treatment success (IOP reduction of at least 20% from baseline without an increase in medications), and adverse events. Outcome assessment was performed by a second ophthalmologist masked to allocation and to clinical history.

Conditions

  • Open-Angle Glaucoma
  • Ocular Hypertension

Interventions

  • Selective laser trabeculoplastyDevice

    Nanosecond-pulse laser trabeculoplasty delivered over 360 degrees with a Tango laser (Ellex Medical Lasers, Adelaide, Australia) after two drops of pilocarpine 2% and topical anaesthetic.

  • Micropulse laser trabeculoplastyDevice

    Micropulsed 577-nm laser trabeculoplasty delivered over 360 degrees with an IQ 577 laser (Iridex, Mountain View, California, USA) after two drops of pilocarpine 2% and topical anaesthetic.

  • Pattern laser trabeculoplastyDevice

    Short-exposure pattern laser trabeculoplasty delivered over 360 degrees with a Pascal Streamline 577 (Topcon, Tokyo, Japan) after two drops of pilocarpine 2% and topical anaesthetic.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular pressure at 6 monthsTime frame: 6 months after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Glaucoma Unit, Department of Medicine - Ophthalmology, University of Udine

    Udine, UD, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.